Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer

NCT01081951 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01081951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01081951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 4, 2010
Completion date
December 31, 2026
Enrollment
162 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer